
    
      Follow-up is required until the end of treatment for the purposes of the study for all
      patients by standard hematologic, cytogenetic and molecular criteria. This study will not
      contemplate any additional expense beyond what is expected for a regular follow-up, according
      to the international guidelines for CML.

      Sample Size: target accrual was not defined, all eligible patients observed between January
      2005 and December 2012 will be included.
    
  